Margot Schoenborn is Vice President, Head of Oncology Strategy & Business Management for Laboratory Corporation of America Holdings (“Labcorp”) (NYSE:LH), and S&P 500 company headquartered in Burlington, North Carolina. Margot is responsible for driving the oncology strategy across drug development and diagnostic segments and manages the precision medicine drug development sales and client services teams. Margot joined Labcorp in July 2021 through its acquisition of OmniSeq, Inc., where she served as Chief Executive Officer and Board Director from May 2019 through July 2021. Margot was part of the Roswell Park Comprehensive Cancer Center team, where she served as Deputy General Counsel, that spun out OmniSeq in 2015, and held roles as OmniSeq’s CAO & General Counsel from 2015 through her appointment as CEO of OmniSeq in 2019 after OmniSeq secured its Series B funding. Margot continued as VP, Head of OmniSeq through December 2022 when OmniSeq was fully integrated into Labcorp. Margot is a seasoned business executive and attorney with experience in corporate development, transactions, capital market activities, corporate finance, and leadership of multi-functional teams over 20+ year career in healthcare, state and federal healthcare law enforcement, and commercial litigation. Margot received her JD, cum laude, from University at Buffalo School of Law, where she served as Editor in Chief of the Human Rights Law Review. Margot received her bachelor degree cum laude from Nazareth College. Margot lives in Buffalo, New York with her husband, Jeff, and their two boys.